Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting

Name	World Continuing Education Alliance
Activity Title	Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting
Details	Hepatitis C virus (HCV) infection is an important public health problem worldwide, as many HCV-infected patients develop liver cirrhosis and/or hepatocellular carcinoma (HCC). Recent improvements in the treatment of HCV infection have focused on the use of direct-acting antiviral agents (DAAs). Statins (inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase) have been proposed as a new candidate for the treatment of HCV infection. According to previously conducted clinical studies using statins in HCV-infected patientsn Objectives Course Objective Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs). However, despite successful viral clearance, many patients continue to have HCV-related disease progression. Therefore, new treatments must be developed to achieve viral clearance and prevent the risk of HCV-related diseases
Competence	General Medicine
Start Date	<span class="not-set">(not set)</span>
End Date	<span class="not-set">(not set)</span>
Event Time	02:00 PM
Location	World Continuing Education Alliance eLearning System
Cost (UGX)	0
CPD Points	1